Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Canagliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms CANONICAL Study
- 07 Oct 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.
- 07 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2018 Planned End Date changed from 30 Sep 2019 to 31 Dec 2019.